Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small molecule precision oncology therapies, today announced a definitive ...

The first selective Fatty Acid Binding Protein 5 inhibitor safely administered to human subjects Initial safety and pharmacokinetic data expected during the first half 2025 SOLANA BEACH, Calif., Jan.

A novel topical gel, HT-001, has shown potential as a treatment for cutaneous side effects from epidermal growth factor ...

Patients with HR+/HER2− metastatic breast cancer without previous systemic therapy were randomly assigned to receive either ...

The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...

This agreement will enable Vera to develop and market VT-109 in return for undisclosed upfront and milestone payments.

Pfizer PFE announced positive results from the phase III CREST study that evaluated its investigational PD-1 inhibitor ...

Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...

As of January 6, 2025, there were six evaluable patients in the Phase 2a arm evaluating IMM-1-104 with modified FOLFIRINOX in ...